Why is shotgun metagenomic sequencing becoming a popular technique for clinical laboratory diagnostic testing in difficult cases such as fever of unknown origin?

Why Shotgun Metagenomic Sequencing is Gaining Popularity for Fever of Unknown Origin

Shotgun metagenomic sequencing (mNGS) is becoming popular for difficult diagnostic cases like fever of unknown origin because it offers pathogen-agnostic detection that can identify any microorganism—bacteria, viruses, fungi, or parasites—in a single test without requiring prior suspicion of a specific pathogen, addressing the fundamental limitation of conventional diagnostics that depend on knowing what to look for. 1

Core Advantages Over Conventional Testing

Unbiased Pathogen Detection

The primary driver of mNGS adoption is its culture-independent, hypothesis-free approach that sequences all genetic material in a sample simultaneously 1. This contrasts sharply with:

• Traditional culture: Requires days to weeks (or months for mycobacteria), fails for fastidious organisms, and is impaired by prior antibiotic exposure—resulting in negative blood cultures in many patients with serious infections 1
• Multiplex PCR panels: Limited to pre-selected pathogens (typically 15-25 targets) and cannot detect unexpected or novel organisms 1
• Serology: Requires specific antibody testing and often provides only retrospective diagnosis

Superior Diagnostic Performance in Key Sample Types

A 2021 systematic review and meta-analysis demonstrated clinically relevant sensitivity and specificity 1:

• Blood samples: 90% sensitivity (95% CI: 78-96%) and 86% specificity (45-98%)
• Cerebrospinal fluid: 75% sensitivity (54-89%) and 96% specificity (72-100%)
• Orthopedic samples: 84% sensitivity (79-88%) and 67% specificity (38-87%)

In FUO cohorts specifically, mNGS shows dramatically higher sensitivity than culture (81.5% vs. 47.3% in one study 2; 69.1% vs. 16.9% in another 3), though with lower specificity (73.4% vs. 84.8% 2; 57.6% vs. 96.0% 3).

Rapid Turnaround Time

mNGS can provide results in 4-7 hours in some cases 1, compared to 24-72 hours for conventional culture 1. The median time from sample to result across studies is 29 hours (range: 4-144 hours) 1. This speed is critical because delays >1 day in appropriate antimicrobial therapy are associated with a 2-fold increase in mortality risk in severe infections 1.

Clinical Impact in Fever of Unknown Origin

Diagnostic Yield

In FUO populations where infectious diseases account for 50-70% of cases 3, 2:

• mNGS provides clinically meaningful diagnostic contribution in 31.5% of FUO patients 3
• Blood mNGS increases organism detection by 22.9% compared to culture and 19.8% compared to traditional methods 4
• Early application (within 3 days of admission) significantly reduces time to diagnosis (6.1 vs. 10.5 days) and hospital stay (13.7 vs. 30.3 days) 5

Therapeutic Impact

mNGS results lead to actionable changes in antimicrobial management 3, 5, 6:

• Antibiotic escalation, de-escalation, or comprehensive regimen modification
• Reduced antibiotic consumption (13.3 vs. 19.5 days) and cost (4,543 vs. 9,873 CNY) when applied early 5
• Improved antibiotic stewardship by ruling out infections (negative predictive value: 67.6%) 5

Detection of Difficult Pathogens

mNGS excels at identifying 1, 7, 4:

• Fastidious organisms that cannot be conventionally cultured
• Rare or novel pathogens not included in standard panels
• Coinfections with multiple organisms
• Bloodstream infections (38% improvement over culture) 4

Important Caveats and Limitations

Contamination and False Positives

The ability to detect microbes at very low concentrations is both an advantage and a major challenge 1. Key issues include:

• 76% of studies reported some degree of contamination 1
• Only 62% of studies used negative controls 1
• No consensus exists on bioinformatic thresholds to distinguish true infection from contamination 1
• Lower specificity than culture means positive results require careful clinical correlation 3, 2

Human DNA Interference

A median 91% of sequence reads are classified as human DNA (IQR: 82-98%) even after depletion techniques 1, reducing the depth of pathogen sequencing and requiring improved depletion methods.

Sample Type Matters Critically

Diagnostic yield varies dramatically by specimen 3:

• Drainage fluid/abscess samples: 90.9% diagnostic contribution
• Lesion-directed sampling consistently outperforms blood sampling
• Blood mNGS as first-line test, followed by sampling suspected infection sites as second-line, provides optimal diagnostic strategy 4

Cost Considerations

Consumable costs range from $130 (multiplexed) to $685 (single sample) 1, compared to ~$50 for blood culture 1. However, early mNGS application may offset costs through reduced hospital stays and antibiotic use 5.

Antimicrobial Resistance Prediction

While promising, AMR prediction shows concerning error rates: categorical agreement 88%, but very major error rate 24% and major error rate 5% 1. This technology requires further validation before replacing phenotypic susceptibility testing.

Optimal Clinical Application Strategy

Based on the evidence, mNGS should be deployed strategically rather than as a first-line universal test 3, 6:

1. Consider early mNGS (within 3 days) when:

   • Conventional testing remains negative despite high clinical suspicion for infection
   • Patient has received prior antibiotics (culture yield impaired)
   • Suspected fastidious, rare, or novel pathogen
   • Lower white blood cell count (independently associated with meaningful results, OR 0.87) 3

2. Prioritize specimen selection:

   • Sample directly from suspected infection site when possible (abscess, drainage fluid, tissue)
   • Use blood mNGS for suspected bloodstream infection
   • CSF for neurological infections

3. Interpret results cautiously:

   • Positive results require clinical correlation—not all detected organisms are causative
   • Consider organism abundance, clinical syndrome, and alternative diagnoses
   • Use negative results to support de-escalation decisions (good negative predictive value)

4. Complement, don't replace, conventional testing:

   • mNGS and traditional methods show complementary pathogen detection spectra 6
   • Continue standard microbiological workup in parallel

Regulatory and Quality Control Challenges

Clinical laboratories face significant hurdles before routine implementation 1:

• FDA clearance (US) or CE marking (EU) required for diagnostic platforms
• Need for standardized workflows, quality control protocols, and validated bioinformatic pipelines
• Only 19% and 29% of studies used internal and positive controls, respectively 1
• Accredited workflows for non-expert users remain underdeveloped 1

The technology is on the road to maturity but not yet there 7—current evidence supports use as an adjunctive tool for complex cases rather than routine screening of all FUO patients 6.